SIDEROS-E

 Duchenne Muscular Dystrophy / Posted 12 months ago

Phase III Study With Idebenone in Patients With Duchenne Muscular Dystrophy (SIDEROS-E)

The purpose of the study is to assess the long-term safety and efficacy of idebenone in patients with Duchenne muscular dystrophy (DMD) who completed the SIDEROS study.

The study is an open-label, single-group, multi-center extension study in patients with DMD receiving glucocorticoid steroids who participated in the SIDEROS study and who meet all the inclusion criteria and none of the exclusion criteria for this extension study.

The study consists of 4 study visits scheduled every 6 months (Visit 1/Baseline, Visit 2/Week 26, Visit 3/ Week 52 and Visit 4/ Week 78), and a follow-up visit 4 weeks after treatment discontinuation. Visit 8/Week 78 in SIDEROS study is also SIDEROS-E Visit 1/Baseline.

  • Inclusion Criteria :
    • Completion of the SIDEROS study at Visit 8/ Week 78
    • Signed and dated Informed Consent Form for SIDEROS-E
  • Exclusion Criteria :
    • Patients who discontinued SIDEROS study prematurely (i.e. did not attend all visits from V1 to V8)
    • Safety, tolerability or other issues arising during the course of the SIDEROS study which in the opinion of the Investigator may put the patient at significant risk or may interfere significantly with the patient's participation in the SIDEROS-E study
    • Use of any investigational drug other than the study medication
  • Study start date : 01/07/2018
  • Study end date : 01/12/2023
  • Wales-Based Study Contact : please speak to your clinician
  • Principal Investigator : Jodi Wolff
Contact details

Great Ormond Street Hospital for Children, Leeds Teaching Hospital NHS Trust, UCL, National Hospital for Neurology and Neurosurgery, Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, Clinical Research Facility Level 6 Leazes Wing Royal Victoria Infirmary. England  Show Phone Number sideros@santhera.com bepartofresearch.nihr.ac.uk

No post found